General Announcement::Press Release

Issuer & Securities

Issuer/ Manager
BIOCON BIOLOGICS GLOBAL PLC
Securities
BIOCONBIO US$800M6.67%N291009A - US090978AA56 - RJUB
BIOCONBIO US$800M6.67%N291009R - USG11185AA61 - KSEB
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
07-Mar-2025 21:10:41
Status
New
Announcement Sub Title
Press Release
Announcement Reference
SG250307OTHRGK7S
Submitted By (Co./ Ind. Name)
Biocon Biologics Limited / Akhilesh Nand
Designation
Company Secretary
Effective Date and Time of the event
07/03/2025 18:30:00
Description (Please provide a detailed description of the event in the box below)
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek Biosimilar to Ustekinumab for Chronic Plaque Psoriasis

Attachments

BBL_Phase3Study_Yesintek_SGX_07032025.pdf
Total size =454K